Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152

Günter Emons, Herbert Sindermann, Jürgen Engel, Andrew V Schally, Carsten Gründker

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The luteinizing hormone-releasing hormone (LHRH; also known as gonadotropin-releasing hormone) receptor can be utilized for targeted chemotherapy with cytotoxic LHRH analogues such as AN-152, in which doxorubicin is linked to [D-Lys6]LHRH. Our studies demonstrate receptor-mediated actions of the cytotoxic LHRH analogue AN-152 in LHRH receptor-positive endometrial and ovarian tumors in vivo. Intravenous administration of AN-152 is far less toxic and inhibits the growth of LHRH receptor-positive tumors better than equimolar doses of the cytotoxic agent doxorubicin. AN-152 has no antitumor activity in LHRH receptor-negative cancers. This provides evidence for the principle of targeted cytotoxic chemotherapy to tumor cells expressing LHRH receptors. In addition, we were able to show that LHRH binding sites were only slightly reduced after AN-152 treatment. Therefore, repeated therapy is considered to be possible. The majority (80%) of human endometrial and ovarian cancers and about 50% of breast cancers express LHRH receptors. In addition, apart from reproductive organs, which are normally removed during surgical therapy, other organs and hematopoietic stem cells do not express LHRH receptors. Thus, cytotoxic LHRH analogues such as AN-152 appear to be suitable drugs for a more efficacious and less toxic targeted chemotherapy for endometrial and ovarian cancers. A recently finished phase I study assessed the dose limitations, maximum tolerated dose and pharmacokinetics of AN-152 given once every 3 weeks in patients with gynecological and breast cancers. A phase II study was started in January 2008.

Original languageEnglish
Pages (from-to)15-18
Number of pages4
JournalNeuroendocrinology
Volume90
Issue number1
DOIs
StatePublished - Jul 1 2009

Fingerprint

LHRH Receptors
Gonadotropin-Releasing Hormone
Drug Therapy
Poisons
Endometrial Neoplasms
Ovarian Neoplasms
Doxorubicin
Neoplasms
Breast Neoplasms
Maximum Tolerated Dose
Cytotoxins
Hematopoietic Stem Cells
lysine(6)-doxorubicin LHRH
Intravenous Administration
Therapeutics
Pharmacokinetics
Binding Sites
Growth
Pharmaceutical Preparations

Keywords

  • AN-152
  • Gonadotropin-releasing hormone
  • Luteinizing hormone-releasing hormone
  • Receptor-targeted therapy

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems
  • Cellular and Molecular Neuroscience

Cite this

Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. / Emons, Günter; Sindermann, Herbert; Engel, Jürgen; Schally, Andrew V; Gründker, Carsten.

In: Neuroendocrinology, Vol. 90, No. 1, 01.07.2009, p. 15-18.

Research output: Contribution to journalArticle

Emons, Günter ; Sindermann, Herbert ; Engel, Jürgen ; Schally, Andrew V ; Gründker, Carsten. / Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. In: Neuroendocrinology. 2009 ; Vol. 90, No. 1. pp. 15-18.
@article{3a8c3a961def4f5a870b9802e0780413,
title = "Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152",
abstract = "The luteinizing hormone-releasing hormone (LHRH; also known as gonadotropin-releasing hormone) receptor can be utilized for targeted chemotherapy with cytotoxic LHRH analogues such as AN-152, in which doxorubicin is linked to [D-Lys6]LHRH. Our studies demonstrate receptor-mediated actions of the cytotoxic LHRH analogue AN-152 in LHRH receptor-positive endometrial and ovarian tumors in vivo. Intravenous administration of AN-152 is far less toxic and inhibits the growth of LHRH receptor-positive tumors better than equimolar doses of the cytotoxic agent doxorubicin. AN-152 has no antitumor activity in LHRH receptor-negative cancers. This provides evidence for the principle of targeted cytotoxic chemotherapy to tumor cells expressing LHRH receptors. In addition, we were able to show that LHRH binding sites were only slightly reduced after AN-152 treatment. Therefore, repeated therapy is considered to be possible. The majority (80{\%}) of human endometrial and ovarian cancers and about 50{\%} of breast cancers express LHRH receptors. In addition, apart from reproductive organs, which are normally removed during surgical therapy, other organs and hematopoietic stem cells do not express LHRH receptors. Thus, cytotoxic LHRH analogues such as AN-152 appear to be suitable drugs for a more efficacious and less toxic targeted chemotherapy for endometrial and ovarian cancers. A recently finished phase I study assessed the dose limitations, maximum tolerated dose and pharmacokinetics of AN-152 given once every 3 weeks in patients with gynecological and breast cancers. A phase II study was started in January 2008.",
keywords = "AN-152, Gonadotropin-releasing hormone, Luteinizing hormone-releasing hormone, Receptor-targeted therapy",
author = "G{\"u}nter Emons and Herbert Sindermann and J{\"u}rgen Engel and Schally, {Andrew V} and Carsten Gr{\"u}ndker",
year = "2009",
month = "7",
day = "1",
doi = "10.1159/000225410",
language = "English",
volume = "90",
pages = "15--18",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152

AU - Emons, Günter

AU - Sindermann, Herbert

AU - Engel, Jürgen

AU - Schally, Andrew V

AU - Gründker, Carsten

PY - 2009/7/1

Y1 - 2009/7/1

N2 - The luteinizing hormone-releasing hormone (LHRH; also known as gonadotropin-releasing hormone) receptor can be utilized for targeted chemotherapy with cytotoxic LHRH analogues such as AN-152, in which doxorubicin is linked to [D-Lys6]LHRH. Our studies demonstrate receptor-mediated actions of the cytotoxic LHRH analogue AN-152 in LHRH receptor-positive endometrial and ovarian tumors in vivo. Intravenous administration of AN-152 is far less toxic and inhibits the growth of LHRH receptor-positive tumors better than equimolar doses of the cytotoxic agent doxorubicin. AN-152 has no antitumor activity in LHRH receptor-negative cancers. This provides evidence for the principle of targeted cytotoxic chemotherapy to tumor cells expressing LHRH receptors. In addition, we were able to show that LHRH binding sites were only slightly reduced after AN-152 treatment. Therefore, repeated therapy is considered to be possible. The majority (80%) of human endometrial and ovarian cancers and about 50% of breast cancers express LHRH receptors. In addition, apart from reproductive organs, which are normally removed during surgical therapy, other organs and hematopoietic stem cells do not express LHRH receptors. Thus, cytotoxic LHRH analogues such as AN-152 appear to be suitable drugs for a more efficacious and less toxic targeted chemotherapy for endometrial and ovarian cancers. A recently finished phase I study assessed the dose limitations, maximum tolerated dose and pharmacokinetics of AN-152 given once every 3 weeks in patients with gynecological and breast cancers. A phase II study was started in January 2008.

AB - The luteinizing hormone-releasing hormone (LHRH; also known as gonadotropin-releasing hormone) receptor can be utilized for targeted chemotherapy with cytotoxic LHRH analogues such as AN-152, in which doxorubicin is linked to [D-Lys6]LHRH. Our studies demonstrate receptor-mediated actions of the cytotoxic LHRH analogue AN-152 in LHRH receptor-positive endometrial and ovarian tumors in vivo. Intravenous administration of AN-152 is far less toxic and inhibits the growth of LHRH receptor-positive tumors better than equimolar doses of the cytotoxic agent doxorubicin. AN-152 has no antitumor activity in LHRH receptor-negative cancers. This provides evidence for the principle of targeted cytotoxic chemotherapy to tumor cells expressing LHRH receptors. In addition, we were able to show that LHRH binding sites were only slightly reduced after AN-152 treatment. Therefore, repeated therapy is considered to be possible. The majority (80%) of human endometrial and ovarian cancers and about 50% of breast cancers express LHRH receptors. In addition, apart from reproductive organs, which are normally removed during surgical therapy, other organs and hematopoietic stem cells do not express LHRH receptors. Thus, cytotoxic LHRH analogues such as AN-152 appear to be suitable drugs for a more efficacious and less toxic targeted chemotherapy for endometrial and ovarian cancers. A recently finished phase I study assessed the dose limitations, maximum tolerated dose and pharmacokinetics of AN-152 given once every 3 weeks in patients with gynecological and breast cancers. A phase II study was started in January 2008.

KW - AN-152

KW - Gonadotropin-releasing hormone

KW - Luteinizing hormone-releasing hormone

KW - Receptor-targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=67651113824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651113824&partnerID=8YFLogxK

U2 - 10.1159/000225410

DO - 10.1159/000225410

M3 - Article

VL - 90

SP - 15

EP - 18

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 1

ER -